Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Landry

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Pediatric Infectious Disease Journal|November 12, 2005
Safety and immunogenicity of palivizumab (Synagis) administered for two seasonsDonald Null, Bernard Pollara, Penelope H Dennehy, et al.
Zootaxa|November 14, 2019
An illustrated catalogue of the Neotropical Gracillariidae (Lepidoptera) with new data on primary typesJurate DE Prins, Helber Adrián Arévalo-Maldonado, Donald R Davis, et al.
Vaccine|February 3, 2012
A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunityDaniel F Hoft, Azra Blazevic, Jaime Stanley, et al.
The Pediatric Infectious Disease Journal|August 8, 2015
Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected ChildrenKany Kany A Luabeya, Michele D Tameris, Hennie D Geldenhuys, et al.
Plos One|May 13, 2017
Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901C Fordham von Reyn, Timothy Lahey, Robert D Arbeit, et al.
Tuberculosis (Edinburgh, Scotland)|February 16, 2013
Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCGMichele Tameris, Helen McShane, J Bruce McClain, et al.
Plos One|November 4, 2015
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy AdultsSharon Sheehan, Stephanie A Harris, Iman Satti, et al.
The New England Journal of Medicine|July 12, 2018
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG RevaccinationElisa Nemes, Hennie Geldenhuys, Virginie Rozot, et al.
JCI Insight|November 8, 2019
Cytomegalovirus infection is a risk factor for tuberculosis disease in infantsJulius Müller, Rachel Tanner, Magali Matsumiya, et al.
Nature Communications|April 13, 2016
T-cell activation is an immune correlate of risk in BCG vaccinated infantsHelen A Fletcher, Margaret A Snowden, Bernard Landry, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Pediatric Infectious Disease Journal|November 12, 2005
Safety and immunogenicity of palivizumab (Synagis) administered for two seasonsDonald Null, Bernard Pollara, Penelope H Dennehy, et al.
Zootaxa|November 14, 2019
An illustrated catalogue of the Neotropical Gracillariidae (Lepidoptera) with new data on primary typesJurate DE Prins, Helber Adrián Arévalo-Maldonado, Donald R Davis, et al.
Vaccine|February 3, 2012
A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunityDaniel F Hoft, Azra Blazevic, Jaime Stanley, et al.
The Pediatric Infectious Disease Journal|August 8, 2015
Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected ChildrenKany Kany A Luabeya, Michele D Tameris, Hennie D Geldenhuys, et al.
Plos One|May 13, 2017
Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901C Fordham von Reyn, Timothy Lahey, Robert D Arbeit, et al.
Tuberculosis (Edinburgh, Scotland)|February 16, 2013
Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCGMichele Tameris, Helen McShane, J Bruce McClain, et al.
Plos One|November 4, 2015
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy AdultsSharon Sheehan, Stephanie A Harris, Iman Satti, et al.
The New England Journal of Medicine|July 12, 2018
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG RevaccinationElisa Nemes, Hennie Geldenhuys, Virginie Rozot, et al.
JCI Insight|November 8, 2019
Cytomegalovirus infection is a risk factor for tuberculosis disease in infantsJulius Müller, Rachel Tanner, Magali Matsumiya, et al.
Nature Communications|April 13, 2016
T-cell activation is an immune correlate of risk in BCG vaccinated infantsHelen A Fletcher, Margaret A Snowden, Bernard Landry, et al.
Pageof 3